These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6786896)

  • 1. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy.
    Hoffmann F; von Unruh GE; Jancik BC
    Eur J Clin Pharmacol; 1981; 19(5):383-5. PubMed ID: 6786896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of carnitine on the metabolism of valproic acid in epileptic patients.
    Sakemi K; Hayasaka K; Tahara M; Sanada Y; Takada G
    Tohoku J Exp Med; 1992 Jun; 167(2):89-92. PubMed ID: 1475789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of valproic acid kinetics in patients during maintenance therapy using a tetradeuterated form of the drug.
    von Unruh GE; Jancik BC; Hoffman F
    Biomed Mass Spectrom; 1980 Apr; 7(4):164-7. PubMed ID: 6778521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy.
    Cloyd JC; Kriel RL; Fischer JH; Sawchuk RJ; Eggerth RM
    Neurology; 1983 Feb; 33(2):185-91. PubMed ID: 6401848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics.
    Hall K; Otten N; Johnston B; Irvine-Meek J; Leroux M; Seshia S
    J Clin Pharmacol; 1985; 25(4):261-8. PubMed ID: 3924980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment.
    Chiba K; Suganuma T; Ishizaki T; Iriki T; Shirai Y; Naitoh H; Hori M
    J Pediatr; 1985 Apr; 106(4):653-8. PubMed ID: 3920375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.
    Suzuki Y; Itoh H; Abe T; Nishimura F; Sato Y; Takeyama M
    J Pharm Pharmacol; 2011 Jul; 63(7):976-81. PubMed ID: 21635265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
    EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
    Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state valproate pharmacokinetics during long term therapy.
    Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
    Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy.
    Yoshida H; Hirozane K; Kimoto H; Hayashi T; Akiyama T; Katayama H; Watanabe M; Yoshitomi H; Kamiya A
    Biol Pharm Bull; 1999 Jul; 22(7):716-20. PubMed ID: 10443469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy.
    Otten N; Hall K; Irvine-Meek J; Leroux M; Budnik D; Seshia S
    Can J Neurol Sci; 1984 Nov; 11(4):457-60. PubMed ID: 6440705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of renal function in epileptic children and teenagers treated with valproic acid or carbamazepine in concomitant therapy with tiagabine].
    Hurkacz M; Wiela-Hojeńska A; Orzechowska-Juzwenko K; Kozik A; Unolt J
    Pol Merkur Lekarski; 2001 Dec; 11(66):480-3. PubMed ID: 11899842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration of metabolites of valproic acid in plasma of epileptic patients.
    Löscher W
    Epilepsia; 1981 Apr; 22(2):169-78. PubMed ID: 6781893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of sodium valproate in epileptic patients.
    Perucca E; Gatti G; Frigo GM; Crema A; Calzetti S; Visintini D
    Br J Clin Pharmacol; 1978 Jun; 5(6):495-9. PubMed ID: 350251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child.
    Orr JM; Farrell K; Abbott FS; Ferguson S; Godolphin WJ
    Eur J Clin Pharmacol; 1983; 24(3):387-90. PubMed ID: 6407847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children.
    Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF
    Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.